Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues

被引:18
作者
Bergeron, Raymond J. [1 ]
Wiegand, Jan [1 ]
McManis, James S. [1 ]
Bharti, Neelam [1 ]
Singh, Shailendra [1 ]
机构
[1] Univ Florida, Dept Med Chem, Gainesville, FL 32610 USA
关键词
D O I
10.1021/jm800154m
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of iron-clearing efficiencies (ICEs), ferrokinetics, and toxicity studies for (S)-2-(2,4-dihydroxyphenyl)4,5-dihydro-4-methyl-4-thiazolecarboxylic acid (deferitrin, 1), (S)-4,5-dihydro-2-[2-hydroxy-4-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylic acid (2), and (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyll-4-methyl-4-thiazolecarboxylic acid (3) are reported. The ICEs in rodents are shown to be dose-dependent and saturable for ligands 2 and 3 and superior to 1. Both polyether analogues in subcutaneous (sc) versus oral (po) administration in rodents and primates demonstrated excellent bioavailability. Finally, in a series of toxicity studies of ligands 1-3, the dosing regimen was shown to have a profound effect in animals treated with ligand 1. When ligand I was given at doses of 237 mu mol/kg/day twice a day (b.i.d.), there was serious proximal tubule damage versus 474,mu mol/kg/day once daily (s.i.d.). With 2 and 3, in iron-overloaded and/or non-iron-loaded rodents, kidney histopathologies remained normal.
引用
收藏
页码:3913 / 3923
页数:11
相关论文
共 64 条
  • [1] Hepatic iron concentration and total body iron stores in thalassemia major.
    Angelucci, E
    Brittenham, GM
    McLaren, CE
    Ripalti, M
    Baronciani, D
    Giardini, C
    Galimberti, M
    Polchi, P
    Lucarelli, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (05) : 327 - 331
  • [2] OXYGEN RADICALS IN ULCERATIVE-COLITIS
    BABBS, CF
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 1992, 13 (02) : 169 - 181
  • [3] Heme, heme oxygenase, and ferritin: How the vascular endothelium survives (and dies) in an iron-rich environment
    Balla, Jozsef
    Vercellotti, Gregory M.
    Jeney, Viktoria
    Yachie, Akihiro
    Varga, Zsuzsa
    Jacob, Harry S.
    Eaton, John W.
    Balla, Gyoergy
    [J]. ANTIOXIDANTS & REDOX SIGNALING, 2007, 9 (12) : 2119 - 2137
  • [4] Impact of the 3,6,9-trioxadecyloxy group on desazadesferrithiocin analogue iron clearance and organ distribution
    Bergeron, Raymond J.
    Wiegand, Jan
    Bharti, Neelam
    Singh, Shailendra
    Rocca, James R.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (14) : 3302 - 3313
  • [5] The design, synthesis, and evaluation of organ-specific iron chelators
    Bergeron, Raymond J.
    Wiegand, Jan
    McManis, James S.
    Bharti, Neelam
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (24) : 7032 - 7043
  • [6] BERGERON RJ, 1993, BLOOD, V81, P2166
  • [7] The origin of the differences in (R)- and (S)-desmethyldesferrithiocin - Iron-clearing properties
    Bergeron, RJ
    Wiegand, J
    Ratliff-Thompson, K
    Weimar, WR
    [J]. COOLEYS ANEMIA: SEVENTH SYMPOSIUM, 1998, 850 : 202 - 216
  • [8] (S)-4,5-dihydro-2-( 2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers:: A solution to nephrotoxicity
    Bergeron, RJ
    Wiegand, J
    McManis, JS
    Vinson, JRT
    Yao, H
    Bharti, N
    Rocca, JR
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (09) : 2772 - 2783
  • [9] Polyamine-vectored iron chelators: The role of charge
    Bergeron, RJ
    Bharti, N
    Wiegand, J
    McManis, JS
    Yao, H
    Prokai, L
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (12) : 4120 - 4137
  • [10] Partition-variant desferrithiocin analogues: Organ targeting and increased iron clearance
    Bergeron, RJ
    Wiegand, J
    McManis, JS
    Weimar, WR
    Park, JH
    Eiler-McManis, E
    Bergeron, J
    Brittenham, GM
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (03) : 821 - 831